Brokerages expect Avanos Medical Inc (NYSE:AVNS) to report $0.33 earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have provided estimates for Avanos Medical’s earnings. The lowest EPS estimate is $0.31 and the highest is $0.34. Avanos Medical also posted earnings of $0.33 per share during the same quarter last year. The business is expected to issue its next earnings report on Tuesday, February 25th.
According to Zacks, analysts expect that Avanos Medical will report full-year earnings of $1.07 per share for the current fiscal year, with EPS estimates ranging from $1.03 to $1.17. For the next fiscal year, analysts expect that the firm will post earnings of $1.37 per share, with EPS estimates ranging from $1.15 to $1.78. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Avanos Medical.
Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.02). Avanos Medical had a positive return on equity of 3.92% and a negative net margin of 6.20%. The company had revenue of $171.40 million for the quarter, compared to analyst estimates of $179.98 million. During the same period in the previous year, the business posted $0.37 earnings per share. The firm’s revenue was up 3.8% compared to the same quarter last year.
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of Avanos Medical by 0.4% during the 2nd quarter. BlackRock Inc. now owns 5,465,732 shares of the company’s stock valued at $238,360,000 after acquiring an additional 23,000 shares during the period. Victory Capital Management Inc. lifted its position in shares of Avanos Medical by 4.3% during the 2nd quarter. Victory Capital Management Inc. now owns 2,291,582 shares of the company’s stock valued at $99,936,000 after acquiring an additional 94,857 shares during the period. Paradice Investment Management LLC lifted its position in shares of Avanos Medical by 12.9% during the 3rd quarter. Paradice Investment Management LLC now owns 2,248,108 shares of the company’s stock valued at $84,214,000 after acquiring an additional 256,525 shares during the period. Invesco Ltd. lifted its position in shares of Avanos Medical by 21.0% during the 2nd quarter. Invesco Ltd. now owns 1,637,165 shares of the company’s stock valued at $71,396,000 after acquiring an additional 284,234 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Avanos Medical by 6.7% during the 2nd quarter. Northern Trust Corp now owns 1,371,355 shares of the company’s stock valued at $59,805,000 after acquiring an additional 85,694 shares during the period. Institutional investors own 94.40% of the company’s stock.
Shares of AVNS stock opened at $31.89 on Tuesday. The company has a market cap of $1.62 billion, a price-to-earnings ratio of 38.89 and a beta of 1.56. The stock has a 50 day simple moving average of $39.03 and a 200-day simple moving average of $39.76. Avanos Medical has a 12-month low of $31.78 and a 12-month high of $53.45. The company has a current ratio of 2.51, a quick ratio of 1.84 and a debt-to-equity ratio of 0.25.
Avanos Medical Company Profile
Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.
Further Reading: Oversold
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.